Companies › Reviva Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Brilaroxazine (RP5063) Dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist | DRD2, HT1A | Phase 3 | Schizophrenia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05184335 | Brilaroxazine (RP5063) | Phase 3 | Schizophrenia | Psychiatry | Feb 2025 |
Cash of $20m on 2026-06-30; operating cash outflow about $12m a year; runway about 20 months at that burn, to Feb 2028
Press releases filed as 8-K in the last year:
LB Pharmaceuticals Gedeon Richter Minerva Neurosciences VistaGen Therapeutics Curemark
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.